Caracterización del tratamiento del dolor oncológico con morfina en el Hospital Oncológico Provincial "Marie Curie" de Camagüey
Fecha
2021
Autores
Olivera Hernández, Norisleidys
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad Central ‘‘Marta Abreu’’ de Las Villas. Facultad de Química y Farmacia. Departamento de Farmacia
Resumen
Se desarrolló un estudio descriptivo, retrospectivo y transversal en el Hospital Provincial Oncológico “Marie Curie” de la provincia Camagüey en el período comprendido entre el 1 de noviembre de 2020 y el 31 de octubre de 2021, con el objetivo de caracterizar el consumo de morfina mediante la evaluación de su prescripción a pacientes con dolor por cáncer y el cálculo de la Dosis Diaria Definida DDD/100camas/día. La muestra de estudio quedó conformada por 21 pacientes (14 mujeres y 7 hombres) con una edad promedio de 55,6 ± 9,9 años, identificándose la Hipertensión Arterial (HTA) como el antecedente patológico personal de mayor incidencia y las localizaciones anatómicas de la lesión más frecuentes fueron mama y cérvico-uterino. Doce pacientes presentaron estilos de vida que incluyeron hábitos tóxicos (tabaquismo y alcoholismo). La evaluación del dolor empleando la escala visual analógica (EVA) se describió en el 43 % de los casos. La prescripción de morfina se evaluó como parcialmente adecuada detectándose dificultades referentes a la indicación y combinaciones medicamentosas. Se identificaron 20 Resultados Negativos Asociados a la Medicación (RNM) por inseguridad no cuantitativa, presentes en casi todos los sujetos de estudio, destacándose la constipación como la de mayor frecuencia. El valor obtenido para la DDD/100camas/día para la morfina de 10 y 20 mg fue de 0,05 y 0,03 respectivamente, reflejando el bajo consumo del fármaco y un inadecuado manejo del dolor oncológico.
A descriptive, retrospective and cross-sectional study was developed at the “Marie Curie” Provincial Oncological Hospital of the Camagüey province in the period between November 1, 2020 and October 31, 2021, with the aim of characterizing the consumption of morphine by evaluating its prescription to patients with cancer pain and calculating the DDD/100beds/day. The study sample consisted of 21 patients (14 women and 7 men) with an average age of 55.6 ± 9.9 years, identifying the arterial hypertension as the personal pathological antecedent with the highest incidence and the most frequent anatomical locations of the lesion they were breast and uterine cervix. Twelve patients present lifestyles that include toxic habits (smoking and alcoholism). Pain assessment using the visual analog scale (VAS) was described in 43 % of the cases. The prescription of morphine was evaluated as partially adequate, detecting difficulties regarding the indication and drug combinations. 20 NRMs were identified due to non-quantitative insecurity, present in almost all study subjects, highlighting constipation as the most frequent. The value obtained for the defined daily dose (DDD) DDD/100 beds/day for morphine of 10 and 20 mg was 0.05 and 0.03 respectively, reflecting the low consumption of the drug and inadequate management of cancer pain.
A descriptive, retrospective and cross-sectional study was developed at the “Marie Curie” Provincial Oncological Hospital of the Camagüey province in the period between November 1, 2020 and October 31, 2021, with the aim of characterizing the consumption of morphine by evaluating its prescription to patients with cancer pain and calculating the DDD/100beds/day. The study sample consisted of 21 patients (14 women and 7 men) with an average age of 55.6 ± 9.9 years, identifying the arterial hypertension as the personal pathological antecedent with the highest incidence and the most frequent anatomical locations of the lesion they were breast and uterine cervix. Twelve patients present lifestyles that include toxic habits (smoking and alcoholism). Pain assessment using the visual analog scale (VAS) was described in 43 % of the cases. The prescription of morphine was evaluated as partially adequate, detecting difficulties regarding the indication and drug combinations. 20 NRMs were identified due to non-quantitative insecurity, present in almost all study subjects, highlighting constipation as the most frequent. The value obtained for the defined daily dose (DDD) DDD/100 beds/day for morphine of 10 and 20 mg was 0.05 and 0.03 respectively, reflecting the low consumption of the drug and inadequate management of cancer pain.
Descripción
Palabras clave
Dolor en Cáncer, Morfina, Administración del Tratamiento Farmacológico